p>
Three
months away from closing, India’s first biotech focused national fund
APIDC-VCL has reached a corpus of Rs 81 crore. Sarath Naru, MD APIDC-VCL, is
confident that it will cross Rs 100 crore and is quite likely to touch the
targeted figure of Rs 150 crore. In an interview with Nandita Singh of
CyberMedia News, Naru shares the success so far and APIDC-VC’s future plans.
How far has the venture fund come
since its launch as against your projections?
We are pretty pleased with our progress. On the fund raising
side the numbers do the talking. We have raised Rs 81 crore and expect to close
way above Rs 100 crore. We have also been successful in attracting talent in our
core team, which I classify as a big achievement. We have been able to attract N
Vaghul of ICICI. He brings with him a wealth of fund management experience. Then
we have Dr SM Balasubra-maniyam who has been instrumental in building seven
biotech companies in the US. The cross border experience that he brings is of
great value in helping the companies we invest in establish. In terms of support
and network formation to support and handhold the companies we invest in, we
have signed a MoU with CSIR for technology sharing and commercialization. This
will allow our portfolio companies to use CSIR facilities. We have also signed a
MoU with Administrative Staff College of India (ASCI) to handhold our portfolio
companies in business plan building and train the entrepreneurs in business
management. Now, we are focusing on deal generation, which involves attracting
good proposals.
How many companies has APIDC-VC
funded so far?
We have so far made investment commitments of Rs 14 crore to
five companies. Three of them - BioServe Biotechnologies, Genomik Design
Pharmaceuticals, Silico Insights - are in various stages of operations and the
other two will also start work soon. We will be finalizing another three
companies in our next round of funding.
Are you concentrating on any
specific areas of biotechnology?
So far the companies we have funded have primarily been
service driven and have all been US-India ventures. Now we are looking at purely
Indian companies and would be delighted to fund companies which are making use
of India’s rich plant biodiversity say in the area of alternative fuels and
those who want to get into contract manufacturing, research
and clinical trials. And then of course those in orphan drugs, which nobody
wants to take up but nevertheless are of high value to third world countries. In
case the project requires more than what we can fund we will go all out to help
arrange for additional funding too.
What’s the total number of
proposals you have received so far?
150. Now we would like to focus on attracting good proposals.
Given the size of fund we should spend each year, Rs 25 crore in funding, the
number of good proposals we receive is not impressive. Here I would like to say
entrepreneurs should rise up to take advantage of the opportunity the field
offers.
What the fund’s exit policy like?
We are aiming that at least 20 percent of our portfolio companies are listed
by the close of the 10-year life of the fund. There is also a provision of third
party strategic investor to come in to take the companies further from where we
leave.
Nandita Singh
Page(s) 1 |